title: Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation.
abstract: Nuclear phosphoinositide-phospholipase C (PI-PLC) beta1 plays a crucial role in the molecular steps that regulate cell proliferation and differentiation in several experimental models, such as myoblasts and hematopoietic cells, via interaction with other important molecular players. Indeed, PI-PLCbeta1 and its related molecules are definitely involved in hematopoiesis, and particularly in drug-induced myeloid or erythroid differentiation. Here, we review the role of nuclear PI-PLCbeta1 signalling in normal hematopoiesis, in pathogenesis and in drug-related induction of hematopoietic differentiation, with particular reference to the current therapy of Myelodysplastic Syndromes (MDS).
authors.forename: Sara
authors.initials: S
authors.lastname: Mongiorgi
authors.forename: Matilde Y
authors.initials: MY
authors.lastname: Follo
authors.forename: Yong Ryoul
authors.initials: YR
authors.lastname: Yang
authors.forename: Stefano
authors.initials: S
authors.lastname: Ratti
authors.forename: Lucia
authors.initials: L
authors.lastname: Manzoli
authors.forename: James A
authors.initials: JA
authors.lastname: McCubrey
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Billi
authors.forename: Pann-Ghill
authors.initials: PG
authors.lastname: Suh
authors.affiliation: Cellular Signalling Laboratory, Department of Biomedical and Neuromotor Sciences, University of Bologna, via Irnerio 48, 40126, Bologna, Italy. lucio.cocco@unibo.it.
authors.forename: Lucio
authors.initials: L
authors.lastname: Cocco
mesh_terms: D002454:Cell Differentiation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D054799:Phospholipase C beta / Q000378:metabolism*
chemical_list: D054799:Phospholipase C beta